Biotechnology in the Time of COVID-19 PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Biotechnology in the Time of COVID-19 PDF full book. Access full book title Biotechnology in the Time of COVID-19 by Jeremy M. Levin. Download full books in PDF and EPUB format.
Author: Jeremy M. Levin
Publisher: Rosetta Books
ISBN: 0795352980
Category : Business & Economics
Languages : en
Pages : 263
Get Book Here
Book Description
47 leaders from across the biotechnology industry tell their stories of battling the global scourge of COVID-19. Pandemics have killed at least a half billion people over the past two millennia. But in the age of biotechnology, humanity is no longer defenseless. The biotechnology industry is a diverse community of scientists, doctors, patients, entrepreneurs, investors, bankers, analysts and reporters, all committed to treating and curing disease. Over the past forty years, it has produced medical advances at an electrifying rate. As the COVID-19 pandemic emerged, hundreds of companies quickly pivoted to combating the virus. The contributors to this book offer inside views of this seminal industry, with historical and personal perspectives, lessons learned, and looks into the future. Diverse as these leaders are, they are united by their conviction that science and medicine will light humanity’s way to greater health and longevity.
Author: Jeremy M. Levin
Publisher: Rosetta Books
ISBN: 0795352980
Category : Business & Economics
Languages : en
Pages : 263
Get Book Here
Book Description
47 leaders from across the biotechnology industry tell their stories of battling the global scourge of COVID-19. Pandemics have killed at least a half billion people over the past two millennia. But in the age of biotechnology, humanity is no longer defenseless. The biotechnology industry is a diverse community of scientists, doctors, patients, entrepreneurs, investors, bankers, analysts and reporters, all committed to treating and curing disease. Over the past forty years, it has produced medical advances at an electrifying rate. As the COVID-19 pandemic emerged, hundreds of companies quickly pivoted to combating the virus. The contributors to this book offer inside views of this seminal industry, with historical and personal perspectives, lessons learned, and looks into the future. Diverse as these leaders are, they are united by their conviction that science and medicine will light humanity’s way to greater health and longevity.
Author: Megha Agrawal
Publisher:
ISBN: 9781839686276
Category :
Languages : en
Pages :
Get Book Here
Book Description
Author: Jasper Becker
Publisher: Oxford University Press
ISBN: 1787386120
Category : Political Science
Languages : en
Pages : 267
Get Book Here
Book Description
What might COVID-19 mean for, and reveal about, China's place in the world? The coronavirus pandemic started in Wuhan, home to the leading lab studying the SARS virus and bats. Was that pure coincidence? This book explores what we know, and still don't know, about the origins of COVID-19, and how it was handled in China. We may never get all the answers, but much is already clear: China's record as the origin of earlier pandemics, and its struggle to bring contagious diseases under control; its history as both a victim of biological warfare and a developer of deadly bioweapons. When Covid broke out, Wuhan was building science parks to realise Beijing's ambitions in biotech research. Whoever achieves global leadership of the gene-editing industry stands to harvest great power and wealth. China has already challenged Western technological supremacy with 5G and in other industries. Yet this tiny, invisible virus has cruelly exposed a critical flaw in the Chinese political system: obsessive secrecy. The West wanted to trust the PRC, hoping that, as it prospered, it would become an open society. Made in China reveals how Beijing's leaders have betrayed that trust.
Author: Donald L. Drakeman
Publisher: Oxford University Press
ISBN: 0195084004
Category : Biotechnology industries
Languages : en
Pages : 241
Get Book Here
Book Description
"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--
Author: Sergio Rosales-Mendoza
Publisher: Academic Press
ISBN: 0323902499
Category : Medical
Languages : en
Pages : 411
Get Book Here
Book Description
Biomedical Innovations to Combat COVID-19 provides an updated overview on the development of vaccines, antiviral drugs and nanomaterials, and diagnostic methods for the fight against COVID-19. Perspectives on such technologies are identified, discussed, and enriched with figures for easy understanding and applicability. Furthermore, it contains basic aspects of virology, immunology, and antiviral drugs that are needed to fully appreciate these innovations. This book is split into four sections: introduction, presenting basic virologic and epidemiological aspects of COVID-19; vaccines against COVID-19, discussing their different types and applications used to develop them; diagnostic approaches for SARS-CoV-2, encompassing advanced sensing and microfluidic-based biosensors; and drug development and delivery, where antivirals based on nanomaterials or drugs are presented. It is a valuable source for virologists, biotechnologists, and members of biomedical field interested in learning more about how novel technologies can be applied to fasten the eradication of the COVID-19 and similar pandemics. - Presents updated literature coverage summarizing the most relevant information on COVID-19 - Written by experts from diverse scientific domains in order to provide readers with a thorough view on the subject - Encompasses tables, figures and information trees especially developed for the book in order to condense and highlight key points for quick reference
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309482887
Category : Science
Languages : en
Pages : 241
Get Book Here
Book Description
The American chestnut, whitebark pine, and several species of ash in the eastern United States are just a few of the North American tree species that have been functionally lost or are in jeopardy of being lost due to outbreaks of pathogens and insect pests. New pressures in this century are putting even more trees at risk. Expanded human mobility and global trade are providing pathways for the introduction of nonnative pests for which native tree species may lack resistance. At the same time, climate change is extending the geographic range of both native and nonnative pest species. Biotechnology has the potential to help mitigate threats to North American forests from insects and pathogens through the introduction of pest-resistant traits to forest trees. However, challenges remain: the genetic mechanisms that underlie trees' resistance to pests are poorly understood; the complexity of tree genomes makes incorporating genetic changes a slow and difficult task; and there is a lack of information on the effects of releasing new genotypes into the environment. Forest Health and Biotechnology examines the potential use of biotechnology for mitigating threats to forest tree health and identifies the ecological, economic, and social implications of deploying biotechnology in forests. This report also develops a research agenda to address knowledge gaps about the application of the technology.
Author: Joe Miller
Publisher: St. Martin's Press
ISBN: 1250280370
Category : Biography & Autobiography
Languages : en
Pages : 189
Get Book Here
Book Description
Winners of the Paul Ehrlich Prize The dramatic story of the married scientists who founded BioNTech and developed the first vaccine against COVID-19. Nobody thought it was possible. In mid-January 2020, Ugur Sahin told Özlem Türeci, his wife and decades-long research partner, that a vaccine against what would soon be known as COVID-19 could be developed and safely injected into the arms of millions before the end of the year. His confidence was built upon almost thirty years of research. While working to revolutionize the way that cancerous tumors are treated, the couple had explored a volatile and overlooked molecule called messenger RNA; they believed it could be harnessed to redirect the immune system's forces against any number of diseases. As the founders of BioNTech, they faced widespread skepticism from the scientific community at first; but by the time Sars-Cov-2 was discovered in Wuhan, China, BioNTech was prepared to deploy cutting edge technology and create the world’s first clinically approved inoculation for the coronavirus. The Vaccine draws back the curtain on one of the most important medical breakthroughs of our age; it will reveal how Doctors Sahin and Türeci were able to develop twenty vaccine candidates within weeks, convince Big Pharma to support their ambitious project, navigate political interference from the Trump administration and the European Union, and provide more than three billion doses of the Pfizer/BioNTech vaccine to countries around the world in record time. Written by Joe Miller—the Financial Times’ Frankfurt correspondent who covered BioNTech’s COVID-19 project in real time—with contributions from Sahin and Türeci, as well as interviews with more than sixty scientists, politicians, public health officials, and BioNTech staff, the book covers key events throughout the extraordinary year, as well as exploring the scientific, economic, and personal background of each medical innovation. Crafted to be both completely accessible to the average reader and filled with details that will fascinate seasoned microbiologists, The Vaccine explains the science behind the breakthrough, at a time when public confidence in vaccine safety and efficacy is crucial to bringing an end to this pandemic.
Author: Baoguo Han
Publisher: Elsevier
ISBN: 0128199237
Category : Technology & Engineering
Languages : en
Pages : 588
Get Book Here
Book Description
Nanosensors for Smart Cities covers the fundamental design concepts and emerging applications of nanosensors for the creation of smart city infrastructures. Examples of major applications include logistics management, where nanosensors could be used in active transport tracking devices for smart tracking and tracing, and in agri-food productions, where nanosensors are used in nanochips for identity, and food inspection, and smart storage. This book is essential reading for researchers working in the field of advanced sensors technology, smart city technology and nanotechnology, and stakeholders involved in city management. Nanomaterials based sensors (nanosensors) can offer many advantages over their microcounterparts, including lower power consumption, high sensitivity, lower concentration of analytes, and smaller interaction distance between object and sensor. With the support of artificial intelligence (AI) tools, such as fuzzy logic, genetic algorithms, neural networks, and ambient-intelligence, sensor systems are becoming smarter. - Provides information on the fabrication and fundamental design concepts of nanosensors for intelligent systems - Explores how nanosensors are being used to better monitor and maintain infrastructure services, including street lighting, traffic management and pollution control - Assesses the challenges for creating nanomaterials-enhanced sensors for mass-market consumer products
Author: Germán Velásquez
Publisher: Springer Nature
ISBN: 3030891259
Category : Medical
Languages : en
Pages : 129
Get Book Here
Book Description
This open access book is a collection of research papers on COVID-19 by Germán Velásquez from 2020 and early 2021 that help to answer the question: How can an agency like the World Health Organization (WHO) be given a stronger voice to exercise authority and leadership? The considerable health, economic and social challenges that the world faced at the beginning of 2020 with COVID-19 continued and worsened in many parts of the world in the second-half of 2020 and into 2021. Many of these countries and nations wanted to explore COVID-19 on their own, sometimes without listening to the main international health bodies such as WHO, an agency of the United Nations system with long-standing experience and vast knowledge at the global level and of which all countries in the world are members. In this single volume, the chapters present the progress of thinking and debate — particularly in relation to drugs and vaccines — that would enable a response to the COVID-19 pandemic or to subsequent crises that may arise. Among the topics covered: COVID-19 Vaccines: Between Ethics, Health and Economics Medicines and Intellectual Property: 10 Years of the WHO Global Strategy Re-thinking Global and Local Manufacturing of Medical Products After COVID-19 Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus COVID-19 Shock Intellectual Property and Access to Medicines and Vaccines The World Health Organization Reforms in the Time of COVID-19 Vaccines, Medicines and COVID-19: How Can WHO Be Given a Stronger Voice? is essential reading for negotiators from the 194 member countries of the World Health Organization (WHO); World Trade Organization (WTO) and World Intellectual Property Organization (WIPO) staff participating in these negotiations; academics and students of public health, medicine, health sciences, law, sociology and political science; and intergovernmental organizations and non-governmental organizations that follow the issue of access to treatments and vaccines for COVID-19.
Author: Michael Kinch
Publisher: UNC Press Books
ISBN: 146963063X
Category : Medical
Languages : en
Pages : 355
Get Book Here
Book Description
The introduction of new medicines has dramatically improved the quantity and quality of individual and public health while contributing trillions of dollars to the global economy. In spite of these past successes--and indeed because of them--our ability to deliver new medicines may be quickly coming to an end. Moving from the beginning of the twentieth century to the present, A Prescription for Change reveals how changing business strategies combined with scientific hubris have altered the way new medicines are discovered, with dire implications for both health and the economy. To explain how we have arrived at this pivotal moment, Michael Kinch recounts the history of pharmaceutical and biotechnological advances in the twentieth century. Kinch relates stories of the individuals and organizations that built the modern infrastructure that supports the development of innovative new medicines. He shows that an accelerating cycle of acquisition and downsizing is cannibalizing that infrastructure Kinch demonstrates the dismantling of the pharmaceutical and biotechnological research and development enterprises could also provide opportunities to innovate new models that sustain and expand the introduction of newer and better breakthrough medicines in the years to come.
